From Mild to Serious, Common to Rare: The Adverse Events of Osteoporosis Drugs

A market analysis by Zion Market Research shows that bisphosphonates will reach $14 billion in sales by 2021. This is, in part, due to an burgeoning aging population. These first-line agents currently make up about 48 percent of the total osteoporosis drugs market. As more patients are prescribed bisphosphonates, physicians will increasingly be faced with managing drug-related adverse events from mild to serious to common and rare. Learn more in this article.

References:

Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017;12:43. https://www.ncbi.nlm.nih.gov/pubmed/28425085Eleutherakis-Papaiakovou E, Bamias A. Antiresorptive treatment-associated ONJ. Abstract. Eur J Cancer Care (Engl). 2017;26(6). https://www.ncbi.nlm.nih.gov/pubmed/29063702Fassio A, Bertoldo F, Idolazzi L, et al. Drug-induced osteonecrosis of the jaw: the state of the art. Abstract. Reumatismo 2017;69:9-15. https://www.ncbi.nlm.nih.gov/pubmed/28535616Jagpal A, Saag KG. How to use bisphosphonates safely and optimally. Rheumatology (Oxford). 2018;57:1875-1876. https://www.ncbi.nlm.nih.gov/pubmed/29165674